UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. 5421 Avenida Encinas, Suite F Carlsbad, California 92008 (Address of Principal Executive Offices) (Zip Code) ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2019 Earnings Conference Call November 14, 2019 4:30 PM ET Company Participants Philip Taylor – Gilmartin Group Bart Bandy – Chief Executive Officer Tom Stankovich – Chief Financial Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by, and welcome to the ReShape Lifesciences Third Quarter of 2019 Earnings Conference Call. At this time all participants are in a listen-only mode, and please be advised that today's conference i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1828101 (State of Incorporation) (I.R.S. Employer 5421 Avenida Encina ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2019 Earnings Conference Call August 14, 2019 4:30 PM ET Company Participants Scott Youngstrom - CFO Bart Bandy - CEO Conference Call Participants Operator Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, August 14th, 2019. I would now like to turn the conference call over to Scott Youngstrom, CFO of ReShape Life ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1828101 (State of Incorporation) (I.R.S. Employer 5421 Avenida Encinas, Su ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2019 Earnings Conference Call May 20, 2019 4:30 PM ET Company Participants Scott Youngstrom - CFO Bart Bandy - CEO Conference Call Participants Operator Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, May 20, 2019. I would now like to turn the conference call over to Scott Youngstrom, CFO of ReShape Lifesciences ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1828101 (State of Incorporation) (I.R.S. Employer 5421 Avenida Encinas, S ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q4 2018 Results Earnings Conference Call April 1, 2019 4:30 PM ET Company Participants Scott Youngstrom - Chief Financial Officer Dan Gladney - Chairman and CEO Bart Bandy - Chief Executive Officer Conference Call Participants Operator Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, April 1, 2019. I would now like ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1828101 (State of Incorporation) (I.R.S. E ...